Search results
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues
FOX 59 Indianapolis· 3 days agoRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro,...
Weight-loss drug drives Eli Lilly to raise 2024 sales forecast by $2 billion
Reuters· 2 days ago, opens new tab weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2...
Indiana Fever lands Eli Lilly as jersey patch sponsor - Indianapolis Business Journal
Indianapolis Business Journal· 2 days agoIndianapolis-based pharmaceutical giant Eli Lilly and Co. will sponsor a patch on the shoulder of...
Eli Lilly lifts profit view on diabetes and weight-loss drug strength
WSAU Wausau· 3 days ago(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for...
Eli Lilly (LLY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoImage source: The Motley Fool. Eli Lilly (NYSE: LLY) Q1 2024 Earnings Call Apr 30, 2024, 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers...
...Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition - Catalent...
Benzinga· 22 hours agoNovo Nordisk A/S NVO is witnessing a surge in the number of patients starting on its weight-loss...
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues
San Francisco Chronicle· 3 days agoRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro,...
Eli Lilly and Co (LLY) Surpasses Q1 Earnings Estimates and Raises Full-Year Guidance
GuruFocus.com via Yahoo Finance· 3 days agoKey Product Performance: Mounjaro and Zepbound led revenue growth, with Mounjaro alone generating...
Weight loss drugs are so hot that Eli Lilly is expecting $2 billion more in sales this year
Quartz· 3 days agoEli Lilly stock jumped 5% during Tuesday morning trading to about $773 a share after the pharma giant reported better-than-expected sales of its weight ...
Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY): Anti-Obesity Drug Market Could Reach Double...
The Wall Street Transcript· 4 days agoCiti Research Health Care Analyst Andrew Baum, M.D., maintains a “buy” recommendation on GLP-1...